Ribonucleases as a novel pro-apoptotic anticancer strategy: Review of the preclinical and clinical data for ranpirnase

John Costanzi, David Sidransky, Ami Navon, Howard Goldsweig

Research output: Contribution to journalArticle

Abstract

Cytotoxic ribonucleases (RNases), such as ranpiranase, represent a novel mechanism-based approach to anticancer therapy. These relatively small proteins selectively attack malignant cells, triggering apoptotic response and inhibiting protein synthesis. Ranpirnase, originally isolated from oocytes of Rana pipiens, is a member of a family of endoribonucleases. The anticancer effects of ranpiranase have been documented in both in vitro and in vivo experimental tumor models. The effects of ranpiranase appear to be selective for cancer cells. Based on Phase I study data, the maximum tolerated dose (MTD) was 960 μg/m2, with the dose-limiting toxicity (DLT) characterized by proteinuria with or without azotemia, peripheral edema, and fatigue. Ranpirnase did not induce myelosuppression, mucositis, alopecia, cardiotoxicity, coagulopathy, hepatotoxicity, or adverse metabolic effects. Phase II tumor-specific trials investigated the activity of ranpirnase in malignant mesothelioma, breast cancer, non-small cell lung cancer, and renal cell cancer. A Phase III randomized study in malignant mesothelioma patients compares the combination of ranpirnase plus doxorubicin to doxorubicin monotherapy.

Original languageEnglish (US)
Pages (from-to)643-650
Number of pages8
JournalCancer Investigation
Volume23
Issue number7
DOIs
StatePublished - 2005

Fingerprint

Ribonucleases
Doxorubicin
Endoribonucleases
Rana pipiens
Azotemia
Neoplasms
Mucositis
Maximum Tolerated Dose
Alopecia
Proteinuria
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Oocytes
Fatigue
Edema
Proteins
Theoretical Models
Breast Neoplasms
ranpirnase
Malignant Mesothelioma

Keywords

  • Anticancer therapy
  • Ranpiranase
  • Ribonucleases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ribonucleases as a novel pro-apoptotic anticancer strategy : Review of the preclinical and clinical data for ranpirnase. / Costanzi, John; Sidransky, David; Navon, Ami; Goldsweig, Howard.

In: Cancer Investigation, Vol. 23, No. 7, 2005, p. 643-650.

Research output: Contribution to journalArticle

@article{8b1933503bc449e1808fe05f281c5ab2,
title = "Ribonucleases as a novel pro-apoptotic anticancer strategy: Review of the preclinical and clinical data for ranpirnase",
abstract = "Cytotoxic ribonucleases (RNases), such as ranpiranase, represent a novel mechanism-based approach to anticancer therapy. These relatively small proteins selectively attack malignant cells, triggering apoptotic response and inhibiting protein synthesis. Ranpirnase, originally isolated from oocytes of Rana pipiens, is a member of a family of endoribonucleases. The anticancer effects of ranpiranase have been documented in both in vitro and in vivo experimental tumor models. The effects of ranpiranase appear to be selective for cancer cells. Based on Phase I study data, the maximum tolerated dose (MTD) was 960 μg/m2, with the dose-limiting toxicity (DLT) characterized by proteinuria with or without azotemia, peripheral edema, and fatigue. Ranpirnase did not induce myelosuppression, mucositis, alopecia, cardiotoxicity, coagulopathy, hepatotoxicity, or adverse metabolic effects. Phase II tumor-specific trials investigated the activity of ranpirnase in malignant mesothelioma, breast cancer, non-small cell lung cancer, and renal cell cancer. A Phase III randomized study in malignant mesothelioma patients compares the combination of ranpirnase plus doxorubicin to doxorubicin monotherapy.",
keywords = "Anticancer therapy, Ranpiranase, Ribonucleases",
author = "John Costanzi and David Sidransky and Ami Navon and Howard Goldsweig",
year = "2005",
doi = "10.1080/07357900500283143",
language = "English (US)",
volume = "23",
pages = "643--650",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Ribonucleases as a novel pro-apoptotic anticancer strategy

T2 - Review of the preclinical and clinical data for ranpirnase

AU - Costanzi, John

AU - Sidransky, David

AU - Navon, Ami

AU - Goldsweig, Howard

PY - 2005

Y1 - 2005

N2 - Cytotoxic ribonucleases (RNases), such as ranpiranase, represent a novel mechanism-based approach to anticancer therapy. These relatively small proteins selectively attack malignant cells, triggering apoptotic response and inhibiting protein synthesis. Ranpirnase, originally isolated from oocytes of Rana pipiens, is a member of a family of endoribonucleases. The anticancer effects of ranpiranase have been documented in both in vitro and in vivo experimental tumor models. The effects of ranpiranase appear to be selective for cancer cells. Based on Phase I study data, the maximum tolerated dose (MTD) was 960 μg/m2, with the dose-limiting toxicity (DLT) characterized by proteinuria with or without azotemia, peripheral edema, and fatigue. Ranpirnase did not induce myelosuppression, mucositis, alopecia, cardiotoxicity, coagulopathy, hepatotoxicity, or adverse metabolic effects. Phase II tumor-specific trials investigated the activity of ranpirnase in malignant mesothelioma, breast cancer, non-small cell lung cancer, and renal cell cancer. A Phase III randomized study in malignant mesothelioma patients compares the combination of ranpirnase plus doxorubicin to doxorubicin monotherapy.

AB - Cytotoxic ribonucleases (RNases), such as ranpiranase, represent a novel mechanism-based approach to anticancer therapy. These relatively small proteins selectively attack malignant cells, triggering apoptotic response and inhibiting protein synthesis. Ranpirnase, originally isolated from oocytes of Rana pipiens, is a member of a family of endoribonucleases. The anticancer effects of ranpiranase have been documented in both in vitro and in vivo experimental tumor models. The effects of ranpiranase appear to be selective for cancer cells. Based on Phase I study data, the maximum tolerated dose (MTD) was 960 μg/m2, with the dose-limiting toxicity (DLT) characterized by proteinuria with or without azotemia, peripheral edema, and fatigue. Ranpirnase did not induce myelosuppression, mucositis, alopecia, cardiotoxicity, coagulopathy, hepatotoxicity, or adverse metabolic effects. Phase II tumor-specific trials investigated the activity of ranpirnase in malignant mesothelioma, breast cancer, non-small cell lung cancer, and renal cell cancer. A Phase III randomized study in malignant mesothelioma patients compares the combination of ranpirnase plus doxorubicin to doxorubicin monotherapy.

KW - Anticancer therapy

KW - Ranpiranase

KW - Ribonucleases

UR - http://www.scopus.com/inward/record.url?scp=33344475705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344475705&partnerID=8YFLogxK

U2 - 10.1080/07357900500283143

DO - 10.1080/07357900500283143

M3 - Article

C2 - 16305992

AN - SCOPUS:33344475705

VL - 23

SP - 643

EP - 650

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 7

ER -